New England Research & Management Inc. Makes New $1.13 Million Investment in Boston Scientific Corporation $BSX

Key Points

• New England Research & Management Inc. has invested $1.13 million in Boston Scientific Corporation by purchasing 10,550 shares during the second quarter.
• Boston Scientific reported a strong quarterly earnings performance, with $5.06 billion in revenue and an EPS of $0.75, surpassing estimates.
• Wall Street analysts remain optimistic, with multiple firms raising their price targets for Boston Scientific, indicating an average target of $118.04 and a consensus rating of "Buy."

New England Research & Management Inc. bought a new position in Boston Scientific Corporation (NYSE:BSX - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 10,550 shares of the medical equipment provider's stock, valued at approximately $1,133,000.

Other large investors have also recently added to or reduced their stakes in the company. 1248 Management LLC acquired a new stake in Boston Scientific in the first quarter worth $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific in the first quarter worth $27,000. Investment Management Corp VA ADV bought a new position in shares of Boston Scientific in the fourth quarter worth $25,000. Sunbeam Capital Management LLC bought a new position in shares of Boston Scientific in the fourth quarter worth $26,000. Finally, Ameriflex Group Inc. bought a new position in shares of Boston Scientific in the fourth quarter worth $31,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Boston Scientific stock opened at $99.75 on Tuesday. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $147.80 billion, a PE ratio of 59.38, a price-to-earnings-growth ratio of 2.47 and a beta of 0.65. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The business has a 50 day simple moving average of $104.78 and a 200 day simple moving average of $102.24.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the company posted $0.62 EPS. The business's revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Raymond James Financial raised their target price on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 24th. UBS Group raised their target price on Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Wells Fargo & Company raised their target price on Boston Scientific from $118.00 to $124.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Finally, Robert W. Baird raised their target price on Boston Scientific from $117.00 to $123.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $118.04.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock valued at $18,397,457 in the last three months. Insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.